Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component.

Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component.

A protective malaria vaccine will likely need to elicit both cell-mediated and antibody responses. As adenovirus vaccine vectors induce both these responses in humans, a Phase 1/2a clinical trial was conducted to evaluate the efficacy of an adenovirus serotype 5-vectored malaria vaccine against spor...

Full description

Bibliographic Details
Main Authors: Cindy Tamminga, Martha Sedegah, David Regis, Ilin Chuang, Judith E Epstein, Michele Spring, Jose Mendoza-Silveiras, Shannon McGrath, Santina Maiolatesi, Sharina Reyes, Victoria Steinbeiss, Charlotte Fedders, Kathryn Smith, Brent House, Harini Ganeshan, Jennylynn Lejano, Esteban Abot, Glenna J Banania, Renato Sayo, Fouzia Farooq, Maria Belmonte, Jittawadee Murphy, Jack Komisar, Jackie Williams, Meng Shi, Donald Brambilla, Nalini Manohar, Nancy O Richie, Chloe Wood, Keith Limbach, Noelle B Patterson, Joseph T Bruder, Denise L Doolan, C Richter King, Carter Diggs, Lorraine Soisson, Daniel Carucci, Gail Levine, Sheetij Dutta, Michael R Hollingdale, Christian F Ockenhouse, Thomas L Richie
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3189219?pdf=render

Internet

http://europepmc.org/articles/PMC3189219?pdf=render

Similar Items